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BACKGROUND AND PURPOSE
GPCRs exist in multiple conformations that can engage distinct signalling mechanisms which in turn may lead to diverse
behavioural outputs. In rodent models, activation of the δ opioid receptor (δ-receptor) has been shown to elicit antihyperalgesia,
antidepressant-like effects and convulsions. We recently showed that these δ-receptor-mediated behaviours are differentially
regulated by the GTPase-activating protein regulator of G protein signalling 4 (RGS4), which facilitates termination of G protein
signalling. To further evaluate the signalling mechanisms underlying δ-receptor-mediated antihyperalgesia, antidepressant-like
effects and convulsions, we observed how changes in Gαo or arrestin proteins in vivo affected behaviours elicited by the δ-receptor
agonist SNC80 in mice.
EXPERIMENTAL APPROACH
Transgenic mice with altered expression of various signalling molecules were used in the current studies. Antihyperalgesia was
measured in a nitroglycerin-induced thermal hyperalgesia assay. Antidepressant-like effects were evaluated in the forced swim
test. Mice were also observed for convulsive activity following SNC80 treatment.
KEY RESULTS
In Gαo RGS-insensitive heterozygous knock-in mice, the potency of SNC80 to produce antihyperalgesia and antidepressant-like
effects was enhanced with no change in SNC80-induced convulsions. Conversely, in Gαo heterozygous knockout mice, SNC80-
induced antihyperalgesia was abolished while antidepressant-like effects and convulsions were unaltered. No changes in SNC80-
induced behaviours were observed in arrestin 3 knockout mice. SNC80-induced convulsions were potentiated in arrestin 2
knockout mice.
CONCLUSIONS AND IMPLICATIONS
Taken together, these findings suggest that different signalling molecules may underlie the convulsive effects of the δ-receptor
relative to its antihyperalgesic and antidepressant-like effects.
Abbreviations
CFA, complete Freund’s adjuvant; RGS, regulator of G protein signalling; FST, forced swim test; NTG, nitroglycerin
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Introduction
GPCRs are a diverse family of membrane bound receptors
that regulate a wide array of biological functions. Canoni-
cally, GPCRs regulate these processes through activation of
G proteins which subsequently interact with a variety of
downstream effectors. Following agonist activation, a GPCR
is phosphorylated by GPCR kinases and internalized
following recruitment of arrestins. In recent years, it has
become apparent that GPCRs can signal through G protein-
independent mechanisms (Galandrin et al., 2007) by directly
recruiting arrestins that can also promote signalling from
GPCRs (Reiter et al., 2012). Furthermore, ligands that act at
the same orthosteric site on a receptor can stabilize distinct
active conformations that preferentially signal through
distinct G protein or arrestin subtypes. This phenomenon,
known as functional selectivity or biased agonism, has been
observed with many GPCRs including the β2 adrenoceptor
(Drake et al., 2008), the CB1 cannabinoid receptor (Hudson
et al., 2010), as well as μ-, κ- and δ-opioid receptors (Pradhan
et al., 2012).
The δ opioid receptor (δ-receptor) is a class A GPCR and
interacts with Gαi/o proteins. Activation of the δ-receptor in
rodents has been shown to produce antinociception,
antihyperalgesia, anxiolytic effects and antidepressant-like
effects without the constipation, respiratory depression and
abuse liability observed with μ-receptor agonists (see Chu
Sin Chung and Kieffer, 2013). In addition, some δ-receptor
agonists cause convulsions, which has limited their clinical
utility (Comer et al., 1993; Hong et al., 1998).
The signalling pathways that bring about δ-receptor-
mediated behaviours are only beginning to be understood.
Targeted knockdown of specific G protein subunits using
antisense nucleotides inhibited δ-receptor-mediated spinal
and supraspinal antinociception in mice, implicating multi-
ple Gαi/o subtypes in the regulation of these effects
(Standifer et al., 1996; Sánchez-Blázquez and Gárzon,
1998). Loss of regulator of G protein signalling 4
(RGS4) potentiated the antinociceptive, antihyperalgesic
and antidepressant-like effects of the δ-receptor agonist
SNC80 suggesting that these behaviours are generated
through G protein signalling (Dripps et al., 2017). However,
this study also found that the frequency of SNC80-induced
convulsions was not altered in RGS4 knockout mice
suggesting that δ-receptor-mediated convulsions may signal
through a G protein-independent mechanism. Loss of
arrestin 2 (β-arrestin 1) increased the potency of SNC80 to
induce mechanical antihyperalgesia, whereas loss of arrestin
3 (β-arrestin 2) produced acute tolerance to the antihype-
ralgesic effects of the δ-receptor agonists ARM390 and
JNJ20788560 (Pradhan et al., 2016).
Use of a δ-receptor agonist that is biased towards
producing the analgesic and antidepressant-like effects could
be an effective strategy for improving the safety and clinical
utility of δ-receptor ligands. A detailed understanding of the
intracellular signalling pathways that give rise to δ-receptor-
mediated behaviours, and δ-receptor-mediated convulsions
in particular, is critical for the development of such drugs.
Therefore, to gain a better understanding of the downstream
signalling mechanisms that give rise to δ-receptor-mediated
behaviours, we evaluated how altering Gαo and arrestin
molecules affected these behaviours. Specifically, we
examined the potency of SNC80 to produce antihy-
peralgesia, antidepressant-like effects and convulsions in
Gαo heterozygous knockout mice, Gαo RGS-insensitive het-




All animal care and experimental procedures complied with
the US National Research Council’s Guide for the Care and
Use of Laboratory Animals (Council, 2011). Animal studies
are reported in compliance with the ARRIVE guidelines
(Kilkenny et al., 2010; McGrath and Lilley, 2015). Mice were
group-housed with a maximum of five animals per cage in
clear polypropylene cages with corn cob bedding and nestlets
as enrichment. Mice had free access to food and water at all
times. Animals were housed in pathogen-free rooms
maintained between 68 and 79°F and humidity between 30
and 70% humidity with a 12 h light/dark cycle with lights
on at 07:00 h.
The arrestin 3 knockout mouse strain (Arrb2tm1Rjl/J) was
obtained from The Jackson Laboratory (Bar Harbor, Maine,
https://www.jax.org/strain/011130). Arrestin 2 knockout
mice (Arrb1tm1jse, https://www.jax.org/strain/011131) were
a gift fromDr. Amynah A. Pradhan (University of Illinois
at Chicago). Gαo RGS-insensitive heterozygous knock-in
mice (Goldstein et al., 2009) were obtained from Dr.
Richard Neubig, and Gαo knockout mice were obtained
from Dr. Richard Mortensen (Duan et al., 2007). Mice were
backcrossed at least 10 generations into a C57BL/6 back-
ground and maintained in-house as heterozygote harem
(one male, two females) breeding groups except for arrestin
2 knockout mice which were maintained as homozygote
harem breeding groups. C57BL/6 mice are the background
strain for all the genetic knockout strains used in this
study. C57BL/6 mice were used for all studies as this species
is commonly used in pharmacological and behavioural
research and is consistent with our previous studies (Dripps
et al., 2017). Wild-type littermates (+/+) were used as
controls for all strains except arrestin 2 knockout mice in
which case arrestin 3 wild-type littermates were used. For
studies in which transgenic mice were not required,
C57BL/6 N mice (17–30 g) were obtained from Envigo
(formerly Harlan, Indianapolis, IN, USA). The diet of
breeder mice in the Gαo RGS-insensitive knock-in, Gαo
knockout and arrestin 3 knockout mouse colonies was
supplemented with γ-irradiated peanuts in the shell
(S6711, Bio-Serv, Flemington, NJ, USA) to enhance litter
size and production of transgenic mice.
Experiments were conducted in the housing room during
the light cycle. All mice were used between 8 and 15 weeks of
age at time of experiment and weighed 16–32 g. Mice were
tested only once, and all analyses are between-subject with
the exception of the hot plate test (within-subject analysis).
For in vivo experiments, six mice per experimental condition
(e.g. per drug and per genotype) were used with a total of 904
mice used for the entire study.
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Forced swim test
The forced swim test (FST) is an assay that is widely used to
evaluate the antidepressant-like effects of drugs in rodents
(Barkus, 2013). Our experiments were adapted from Porsolt
et al. (1977) and performed as previously described (Dripps
et al., 2017). Briefly, 60 min after SNC80 (0.1, 0.32, 1, 3.2, 10
or 32 mg·kg1) or vehicle injection, each mouse was placed
in a 4 L beaker filled with 15 cm of 25 ± 1°C water, and its
behaviour was recorded for 6 min using a Sony HDR-CX220
digital camcorder. Videos were analysed by individuals blind
to the experimental conditions, and the amount of time the
animals spent immobile was quantified. Immobility was
defined as the mouse not actively traveling through the water
and making only movements necessary to stay afloat. The
time the mouse spends immobile after the first 30 s of the
assay was recorded.
Nitroglycerin-induced hyperalgesia
The NTG-induced hyperalgesia assay was adapted from Bates
et al. (2010) using modifications described in Pradhan et al.
(2014) and performed as previously described (Dripps et al.,
2017). In brief, male and female mice were used to evaluate
NTG-induced hyperalgesia. Hyperalgesia was assessed by
immersing the tail (~5 cm from the tip) in a 46°C water bath
and determining the latency for the animal to withdraw its
tail with a cut-off time of 60 s. After determining baseline
withdrawal latencies, 10 mg·kg1 NTG (i.p.) was
administered to each animal. Tail withdrawal latency was
assessed again 1 h after NTG administration. At 90 min
post-NTG, animals received an injection of SNC80 (0.32, 1,
3.2, 10 or 32 mg·kg1) or vehicle, and mice were observed
continuously in individual cages for 30 min to observe for
convulsions (see section below). Tail withdrawal latencies
were assessed again 30 min after SNC80 administration.
SNC80-induced convulsions
Mice were observed continuously in individual cages for
convulsions. Unless otherwise noted, NTG treatment had
no significant effect on the frequency or nature of SNC80-
induced convulsions (see Supporting Information). Convul-
sions were typically composed of a single tonic phase
characterized by sudden tensing of the musculature and
extension of the forepaws followed by clonic contractions
that extended the length of the body. Mice would
frequently lose balance and fall on their side, although the
so-called barrel rolling was rarely observed. Convulsions were
followed by a period of catalepsy that lasted 2–5 min after
which the animals were hyperlocomotive but otherwise in-
distinguishable from untreated controls. The severity of each
convulsion was quantified using the following modified Ra-
cine (1972) scale adapted from Jutkiewicz et al. (2006): 1 –
teeth chattering or face twitching; 2 – head bobbing or
twitching; 3 – tonic extension or clonic convulsion lasting
less than 3 s; 4 – tonic extension or clonic convulsion lasting
longer than 3 s; and 5 – tonic extension or clonic convulsion
lasting more than 3 s with loss of balance. Post-convulsion
catalepsy-like behaviour was assessed by placing a horizontal
rod under the forepaws of the mouse, and a positive catalepsy
score was assigned if the mouse did not remove its forepaws
after 30 s. Two arrestin 2 knockout mice that received
32 mg·kg1 SNC80 exhibited sustained convulsions after
the observation period and were killed by pentobarbital
overdose.
Hot plate test
The hot plate test was adapted from Lamberts et al. (2011) and
was chosen because it has previously been used to evaluate
the antinociceptive effects of opioids in arrestin 3 knockout
mice (Bohn et al., 1999). Briefly, mice were placed on a 52°C
hot plate, and the latency to lick forepaw(s) or jump was
measured with a cut-off time of 60 s in order to prevent tissue
damage. To determine baseline latency, mice were placed on
the hot plate 30 min after each of two injections of saline.
Following an injection of 32 mg·kg1 morphine, latency
was assessed every 30 min.
δ-receptor saturation binding
Mice were decapitated following cervical dislocation, the
forebrain was removed immediately, and membranes were
freshly prepared as previously described (Broom et al.,
2002a). Tissue collection without anaesthesia was used to
limit modification to δ-receptor number, conformation
and/or localization and is conditionally acceptable with justi-
fication under the American Veterinary Medical Association
Guidelines for the Euthanasia of Animals. Protein concentra-
tions were determined with a BCA assay kit (Thermo Scien-
tific, Rockford, IL, USA). Specific binding of the δ-receptor
agonist [3H]DPDPE was determined as described using
10 μM of the opioid antagonist naloxone to define non-
specific binding as described by Broom et al., (2002a). Reac-
tions were incubated for 60 min at 26°C and stopped by rapid
filtration through GF/C filter mats soaked in 0.1% PEI using
an MLR-24 harvester (Brandel, Gaithersburg, MD, USA).
Bound [3H]DPDPE was determined by scintillation counting,
and Bmax and Kd values were calculated using nonlinear re-
gression analysis with GraphPad Prism version 6.02
(GraphPad, San Diego, CA, USA). To ensure the reliability of
single values, membranes from each mouse (n = 5 per group)
were assayed in triplicate.
Data and statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). All experiments were randomized.
Six mice per experimental condition were used, from differ-
ent home cages and were evaluated across at least 3 different
days (or experiments or test days). For in vivo studies, power
analysis (α = 0.05; 1-® = 0.9) revealed that for a calculated
effect size of 1–3 (Cohen’s d), depending on the experiment,
a sample size of four to six mice per experimental condition
would be needed (G*Power 3.1.9.2; Faul et al., 2007).
All data analysis was performed using GraphPad Prism
version 6.02 (GraphPad, San Diego, CA, USA). For all tests,
level of significance (α) was set to 0.05. Post hoc analysis was
conducted using the Sidak’s post hoc test to correct for
multiple comparisons. Post hoc analysis was only performed
when F values achieved P < 0.05. All values in the text are
reported as mean ± SEM. ED50 values were calculated using
GraphPad Prism version 6.02 by extrapolating the 50%
maximum effect from the straight line analysis of the
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averaged treatment group data used to generate each dose ef-
fect function.
Materials
All drugs were injected at a volume of 10 mL·kg1unless
otherwise noted. SNC80 ((+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-di-
methyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide)
was dissolved in 1 M HCl and diluted in sterile water to a
concentration of 3% HCl (provided in free base form by
KC Rice, NIDA/NIAA, Rockville, MD). Nitroglycerin (NTG)
was provided by Dr. Adam Lauver (Department of Pharmacol-
ogy and Toxicology, Michigan State University) at a concentra-
tion of 5 mg·mL1 and was diluted in saline. Desipramine
hydrochloride, sumatriptan succinate (Sigma-Aldrich, St.
Louis, MO, USA) and morphine sulfate (NIDA Drug Supply)
were dissolved in saline. All drugs were given s.c. except for
NTGwhich was administered via i.p. injection. The [3H]DPDPE
was purchased from Perkin Elmer (Waltham, MA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharma-
cology.org, the common portal for data from the
IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,
2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b).
Results
δ-receptor-mediated behaviours in Gαo
RGS-insensitive mice
It has previously been demonstrated that loss of RGS4 potenti-
ates δ-receptor-mediated antihyperalgesia and antidepressant-
like effects but not δ-receptor-mediated convulsions (Dripps
et al., 2017). To further investigate the signalling mechanisms
involved in these behaviours, we characterized these behaviours
in Gαo RGS-insensitive heterozygous mice. The Gαo RGS-
insensitive heterozygous mice have one copy of GNAO1 with a
G184S pointmutation that prevents binding of all RGS proteins
to Gαo and should enhance signalling from those G proteins
(Goldstein et al., 2009; Lamberts et al., 2013). First, the potency
of SNC80 to reverse NTG-evoked thermal hyperalgesia was
evaluated in Gαo RGS-insensitive heterozygous mice (+/GS)
and their wild-type littermates (+/+; Figure 1A). The +/GS mice
did not differ significantly from wild-type littermates in their
baseline tail withdrawal latencies prior to NTG treatment (+/+:
42.4 ± 2.5 s, +/GS: 41.4 ± 1.4 s). Administration of 10 mg·kg1
NTG significantly decreased tail withdrawal latency to a similar
degree in both genotypes (+/+: 6.1 ± 1.3 s, +/GS: 5.4 ± 0.3 s).
Two-wayANOVA revealed a significant interaction [SNC80dose
X genotype, F(5,60) = 7.61], as well as significant main effects of
SNC80 dose [F(5,60) = 56.15] and genotype [F(1,60) = 53.07].
There was an approximately 3.5-fold leftward shift in the
SNC80 dose effect curve (ED50 values: +/+: 4.8 mg·kg
1; +/GS:
16.6 mg·kg1) and a significant increase in the maximum effect
observed in the +/GS mice compared with their wild-type
littermates. Overall, the potency and efficacy of SNC80 to
increase tail withdrawal latency was enhanced in Gαo RGS-
insensitive heterozygous mice.
The potency of SNC80-induced antidepressant-like
effects in Gαo RGS-insensitive heterozygous mice was evalu-
ated in the FST (Figure 1B). In the absence of drug treatment,
+/GS mice had lower immobility scores than wild-type litter-
mates. SNC80 significantly decreased immobility scores to a
greater extent in +/GS mice compared to wild-type
littermates. Due to the basal differences in immobility scores,
scores were normalized to a percentage relative to vehicle-
treated mice of the appropriate genotype (Figure 1C). Two-
way ANOVA of the transformed data revealed significant
main effects of SNC80 dose [(vehicle and 0.32–10 mg·kg1
only) F(4,50) = 17.1] and genotype [F(1,50) = 4.80], as well
as a significant interaction [SNC80 dose X genotype,
F(4,50) = 6.23]. To investigate whether Gαo RGS-insensitive
heterozygous mice were hyper-responsive to a wider array of
antidepressive drugs, the effects of the tricyclic antidepres-
sant desipramine were evaluated in the FST (Figure 1D).
Desipramine produced decreases in immobility [main effect
of desipramine dose: F(2,30) = 12.43], but there was no effect
of genotype and no significant interaction.
Although loss of RGS4 did not alter SNC80-induced
convulsions, other RGS proteins may play a role in regulating
this behaviour. Therefore, we evaluated SNC80-induced
convulsions in Gαo RGS-insensitive heterozygous mice and
wild-type littermates and scored convulsion severity using a
modified Racine scale (Figure 1E). SNC80 produced similar
dose-dependent increases in convulsion severity in both
genotypes. There were no significant differences in the fre-
quency of convulsions or time of onset and duration of
SNC80-induced convulsions (see Supporting Information).
It is possible that the enhanced behavioural effects of
SNC80 in Gαo RGS-insensitive heterozygous mice are due
to a change in receptor density or agonist affinity for the
δ-receptor relative to their wild-type littermates. To evaluate
potential changes in these parameters, saturation binding
with the radiolabeled δ-receptor agonist [3H]DPDPE was per-
formed using brain tissue from Gαo RGS-insensitive +/+ and
+/GS mice. There were no significant differences in total
receptor number of the +/GS mice compared to wild-type
littermates (Table 1; Figure 1F). In addition, there were no
changes in the affinity of [3H]DPDPE for the δ-receptor in
the Gαo RGS-insensitive heterozygous mice.
δ-receptor-mediated behaviours in Gαo
heterozygous knockout mice
To further evaluate the role of Gαo in δ-receptor-mediated
behaviours, we characterized δ-receptor-mediated antihype-
ralgesia, antidepressant-like effects and convulsions in Gαo
heterozygous knockout mice. Gαo null mice rarely survived to
weaning (Lamberts et al., 2011). Therefore, we chose to only
evaluate Gαo wild-type and heterozygous knockout mice.
Prior to NTG administration, there were no significant
differences in tail withdrawal latency in Gαo wild-type and
heterozygous knockout mice (+/+: 41.2 ± 1.8 s, +/:
40.3 ± 2.0 s). Administration of 10 mg·kg1 NTG produced
similar decreases in tail withdrawal latency in both genotypes
(+/+: 4.9 ± 0.5 s, +/: 4.1 ± 0.3 s). In Gαo wild-type mice,
SNC80 produced dose-dependent increases in tail withdrawal
latency following NTG administration (Figure 2A). This effect
was absent in Gαo heterozygous knockout mice. Two-way
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ANOVA revealed significant main effects of SNC80 dose [ve-
hicle and 10–100 mg·kg1 only] [F(4,50) = 30.85] and
genotype [F(1,50) = 256.1], as well as a significant interaction
[SNC80 dose X genotype, F(4,50) = 19.04]. To investigate
whether the antihyperalgesic effects of non-δ-receptor drugs
were altered in Gαo heterozygous knockout mice, the effects
of the 5-HT1B/1D receptor agonist sumatriptan onNTG-induced
thermal hyperalgesia were examined (Figure 2B). Sumatriptan
produced similar robust increases in tail withdrawal latency in
wild-type and Gαo heterozygous knockout mice [two-way
ANOVA main effect of sumatriptan dose: F(2,30) = 91.28, but
no main effect of genotype and no interaction].
Table 1







Kd (nM ± SEM)
Gαo RGSi +/+ 99 ± 6 2.5 ± 0.5
Gαo RGSi +/GS 90 ± 5 1.7 ± 0.3
Gαo +/+ 111 ± 11 2.1 ± 0.6
Gαo +/ 108 ± 11 2.8 ± 0.7
Figure 1
(A) Effect of different doses of SNC80 on tail withdrawal latency in NTG-treated Gαo RGS-insensitive wild-type (+/+) and heterozygous (+/GS)
mice. (B, C) Immobility scores of Gαo RGS-insensitive +/+ and +/GS mice in response to SNC80 in the FST expressed as (B) raw immobility scores
or (C) immobility scores normalized to a percentage of the scores of vehicle-treated mice of the appropriate genotype. (D) Effects of desipramine
on immobility scores of Gαo RGS-insensitive +/+ and +/GS mice in the FST. (E) Severity of SNC80-induced convulsions in Gαo RGS-insensitive +/+
and +/GS mice. For panels (A–E), n = 6 mice per group. (F) Saturation binding of [3H]DPDPE to membranes prepared from forebrains of Gαo RGS-
insensitive +/+ or +/GS mice. Each point represents tissue from one mouse assayed in triplicate, n = 5 mice per genotype. *P<0.05, significantly
different from the vehicle treatment group of the same genotype; # P<0.05, significantly different from wild-type mice with same drug dose.
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In the FST, SNC80 produced significant decreases in
immobility in both the Gαo wild-type and heterozygous
knockout mice [Figure 2C; Two-way ANOVA main effect of
SNC80 dose: F(4,50) = 22.05]. However, there were no signif-
icant differences between genotypes in the immobility scores
produced in response to a given dose of SNC80. SNC80 also
produced similar dose-dependent increases in convulsion
severity in Gαo wild-type and heterozygous knockout mice
(Figure 2D). There were no significant differences in fre-
quency of convulsions or the time of onset and duration of
SNC80-induced convulsions (see Supporting Information).
The diminished effect of SNC80 on NTG-induced
hyperalgesia in Gαo heterozygous knockout mice could be
due to decreased receptor density of or agonist affinity at
the δ-receptor relative to wild-type littermates. To evaluate
potential changes in density or agonist affinity, saturation
binding with the radiolabeled δ-receptor agonist [3H]DPDPE
was performed using brain tissue fromGαo wild-type and het-
erozygous knockout mice. There were no significant
differences in total receptor number or affinity of [3H]DPDPE
for the δ-receptor in the Gαo heterozygous knockout mice
relative to wild-type littermates (Table 1; Figure 2E).
δ-receptor-mediated behaviours in arrestin 2
and arrestin 3 knockout mice
To evaluate the potential role of arrestin-mediated mecha-
nisms, we evaluated SNC80-induced antihyperalgesia,
antidepressant-like effects and convulsions in arrestin 2 and
arrestin 3 knockout mice. There were no significant differ-
ences in SNC80-induced antihyperalgesia, antidepressant-
like effects or convulsions in the arrestin 3 knockout mice
compared to wild-type and heterozygote knockout litter-
mates (Figure 3A–C; Supporting Information). However, the
Figure 2
Tail withdrawal latencies in NTG-treated Gαo wild-type (+/+) and heterozygous knockout (+/) mice in response to (A) SNC80 or (B) sumatriptan.
(C) Effects of SNC80 on immobility scores of Gαo +/+ and +/ mice in the FST. (D) Severity of SNC80-induced convulsions in Gαo +/+ and +/
mice. For panels (A–D), n = 6 mice per group. (E) Saturation binding of [3H]DPDPE to membranes prepared from forebrains of Gαo +/+ and
+/ mice. Each point represents tissue from one mouse assayed in triplicate, n = 5 mice per genotype. * P<0.05, significantly different from
the vehicle treatment group of the same genotype; # P<0.05, significantly different from wild-type mice with same drug dose.
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increase in hot-plate latency produced by a single bolus dose
of 32 mg·kg1 morphine in the 52°C hot plate test was poten-
tiated in arrestin 3 knockout mice (Figure 3D) consistent with
previously published data (Bohn et al., 1999; two-way re-
peated measures ANOVA: main effects of time
[F(5,75) = 61.04], genotype [F(2,15) = 13.37] and a significant
interaction [F(10,75) = 6.77]).
In arrestin 2 knockout mice, SNC80-induced increases in
tail withdrawal latency following NTG administration were
similar to wild-type controls (Figure 4A). Arrestin 2 knockout
mice had no significant differences in SNC80-induced
decreases in immobility in the FST relative to wild-type mice
(Figure 4B). In contrast, SNC80-induced convulsions were
profoundly altered in arrestin 2 knockout mice such that the
potency of SNC80 to induce convulsions was significantly
increased in arrestin 2 knockout mice as shown by a leftward
shift in the dose–response curve (Figure 4C). Two-way
ANOVA (vehicle and 1–32 mg·kg1 only) revealed significant
effects of genotype [F(1,50) = 106], SNC80 dose [F(4,50) = 147]
and a significant interaction [F(4,50) = 27.75]. There were no
significant differences in the time of onset and duration of
these convulsions (see Supporting Information). However,
arrestin 2 knockout mice exhibited significantly more
convulsions in response to a single dose of SNC80 relative
with wild-type controls (Figure 4D). Two-way ANOVA
(vehicle and 1–32 mg·kg1 only) revealed significant effects
of genotype [F(1,50) = 26.9], SNC80 dose [F(4,50) = 37.32]
and a significant interaction [F(4,50) = 5.84]. These
subsequent convulsions were similar in nature to the initial
SNC80-induced convulsions, consisting of both tonic and
clonic phases followed by a brief (1–2 min) period of cata-
lepsy. In order to reduce the number of animals used,
SNC80-induced convulsions were typically evaluated prior
to antihyperalgesia measurements (see Methods). However,
these mice received NTG prior to SNC80, which may have
influenced convulsion frequency. Therefore, SNC80-induced
convulsions were also evaluated in drug-naïve mice to
confirm the altered convulsive effects of SNC80 in arrestin 2
knockout mice. NTG administration did not alter convulsion
severity but produced a non-significant increase in the
number of convulsions elicited by 3.2 mg·kg1 SNC80
(Figure 4C, D). Despite the significant changes to SNC80-
induced convulsions observed in arrestin 2 knockout mice,
loss of arrestin 2 did not alter the potency of the chemical
convulsant pentylenetetrazol (see Supporting Information).
Discussion
In this report, we sought to further elucidate the downstream
signalling molecules that give rise to δ-receptor-mediated
behaviours. We found that Gαo and arrestins differentially
regulate the antihyperalgesia, antidepressant-like effects and
convulsions produced by the δ-receptor agonist SNC80. In
the NTG-induced thermal hyperalgesia assay, SNC80 produced
antihyperalgesia in wild-type mice, consistent with previous
Figure 3
(A) Effects of SNC80 on tail withdrawal latencies in NTG-treated arrestin 3 wild-type (+/+), heterozygous (+/) and homozygous (/) knockout
mice. (B) Immobility scores of arrestin 3 +/+, +/ and /mice in the FST following treatment with SNC80. (C) Severity of SNC80-induced con-
vulsions in arrestin 3 +/+, +/ and/mice. (D) Time course of the effects of morphine on hot-plate latency in arrestin 3 +/+, +/ and/mice.
n = 6 per group for all data. * P<0.05, significantly different from wild-type at the same time point.
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studies (Pradhan et al., 2014; Dripps et al., 2017). SNC80 also de-
creased immobility in the FST, consistent with the well-
established antidepressant-like effects of δ-receptor agonists
(Broom et al., 2002b; Naidu et al., 2007; Saitoh et al., 2011). RGS
proteins negatively regulate G protein signalling by accelerating
Gα-mediated GTP hydrolysis which returns Gα to an inactive
state. This function reduces the lifetime of active Gα and dimin-
ishes downstream signalling (Traynor andNeubig, 2005). The po-
tency of SNC80 to produce antihyperalgesia and antidepressant-
like effects was significantly increased in the Gαo RGS-insensitive
heterozygous mice. These data indicate that these δ-receptor-
mediated behaviours signal throughGαo and are negatively regu-
lated by RGS proteins, consistent with our previous finding that
RGS4 negatively regulates these behaviours (Dripps et al., 2017).
Furthermore, these enhanced effects of SNC80 were observed in
micewith only onemutant copy ofGαo, demonstrating that δ-re-
ceptor-mediated signalling in vivo is highly sensitive to the effects
of RGS proteins. Interestingly, the magnitude of these behav-
ioural changes are consistent with those seen in RGS4 knockout
mice, suggesting that other RGS proteins likely do not play a sig-
nificant role in regulating the antihyperalgesic and
antidepressant-like effects of the δ-receptor. Overall, these find-
ings suggest that the enhanced δ-receptor-mediated
antihyperalgesia and antidepressant-like effects observed in the
+/GS mice are likely due to prolongation of δ-receptor-mediated
G protein signalling and amplification of downstream effectors.
To confirm the role of Gαo in δ-receptor-mediated
behaviours, we examined the behavioural effects of SNC80 in
Gαo heterozygous knockout mice. Gαo is highly expressed in
the dorsal root ganglia of the spinal cord and in the brain, com-
prising 0.5–1% of total brain membrane proteins (Yoo et al.,
2002; for review Jiang and Bajpayee, 2009). SNC80-induced
antihyperalgesia was abolished in Gαo heterozygous knockout
mice, suggesting that Gαo is required for the antihyperalgesic ef-
fects of δ-receptor agonists. Furthermore, this profound effect
was produced by only a 50% reduction in Gαo, indicating that
δ-receptor-mediated antihyperalgesia is likely to require robust
amplification of downstream signalling and/or is a high
efficacy-requiring behaviour (i.e. has a small receptor reserve).
It is possible that larger doses of SNC80 could produce
antihyperalgesia in Gαo heterozygous knockout mice; however,
such doses are likely to be non-selective. Taken together, our
findings indicate that Gαo plays a critical role in mediating sig-
nalling required for δ-receptor-mediated antihyperalgesia.
In contrast, decreased expression of Gαo did not affect
δ-receptor-mediated antidepressant-like effects in the FST.
The δ-receptor could be capable of signalling through other
G proteins in order to produce antidepressant-like effects
and/or compensate for the reduction in Gαo expression.
Alternatively, it is possible that the efficacy requirement
for δ-receptor-mediated antidepressant-like effects is rela-
tively low (i.e. has large receptor reserve) compared to that
for δ-receptor-mediated antihyperalgesia in which case one
functional copy of GNAO1 and approximately 50% of Gαo
protein subunits (Lamberts et al., 2011) could be sufficient
to produce a full response in the FST. Broom et al.
Figure 4
(A) Effects of SNC80 on tail withdrawal latencies in NTG-treated arrestin 2 wild-type (+/+) and knockout (/) mice. (B) Immobility scores of
arrestin 2 +/+ and / mice in the FST following treatment with SNC80. (C) Severity of SNC80-induced convulsions in arrestin 2 +/+ and /
mice. (D) Number of SNC80-induced convulsions observed in arrestin 2 +/+ and / mice. n = 6 per group for all data. * P<0.05, significantly
different from the vehicle treatment group of the same genotype; # P<0.05, significantly different from wild-type mice with same drug dose.
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(2002a) proposed that the efficacy requirement for δ-recep-
tor-mediated antinociception was higher than that required
for convulsions. The relative efficacy requirement for
antidepressant-like effects has not been evaluated and will
be compared with efficacy requirements for convulsions
and antihyperalgesic effects in future studies.
In the present study, δ-receptor-mediated convulsions were
not altered in Gαo RGSi and Gαo knockout mice. In addition,
we previously observed that SNC80-induced convulsions were
unaltered in RGS4 knockout mice (Dripps et al., 2017). Overall,
these data may suggest that signalling mechanisms mediating
δ-receptor agonist-induced convulsions are distinct from those
mediating antihyperalgesia and antidepressant-like effects.
These behavioural measures could be regulated differentially
by specific G protein subunits, G protein-independent signal-
ling and/or the selective expression of signalling molecules
within specific brain circuits or regions.
To address this question, we explored the hypothesis that
SNC80-induced convulsions are produced by a G protein-
independent, arrestin-mediated mechanism. As first shown by
Bohn et al. (1999), we observed potentiation of morphine-
induced antinociception in arrestin 3 knockout mice. Although
class AGPCRs are thought to preferentially interact with arrestin
3 (Oakley et al., 2000), no significant changes in δ-receptor-
mediated behaviours, including convulsions, were observed in
arrestin 3 knockout mice. It should be noted that these data
are the result of acute administration of SNC80 and it is possible
that arrestin 3 could play a role in regulating the effects of re-
peated doses of SNC80 or other δ-receptor agonists. This obser-
vation with SNC80 is consistent with previous reports that
found that loss of arrestin 3 in mice did not alter the analgesic
profile of δ-receptor agonists and had no effect on the enhanced
coupling of δ-receptors to voltage-dependent calcium chan-
nels observed in the complete Freund’s adjuvant (CFA) model
of chronic inflammatory pain (Pradhan et al., 2013; Pradhan
et al., 2016). Overall, our findings indicate that arrestin 3 is
not required for δ-receptor-mediated antihyperalgesia,
antidepressant-like effects or convulsions.
In arrestin 2 knockout mice, we observed no changes in
the effects of SNC80 in response to NTG-induced thermal
hyperalgesia. However, it was previously demonstrated that
the effects of SNC80 on CFA-induced mechanical hyperal-
gesia were potentiated in arrestin 2 knockout mice (Pradhan
et al., 2016). It is possible that the δ-receptor-mediated
responses to these distinct pain modalities (CFA vs. NTG;
mechanical vs. thermal) are differentially regulated by
arrestin 2. Further studies should investigate differences in
the signalling molecules and pathways mediating different
types of δ-receptor-mediated antihyperalgesia. The convul-
sive effects of SNC80 were strongly enhanced in arrestin 2
knockout mice. The potency of SNC80 to induce convulsions
was enhanced in arrestin 2 knockout mice, suggesting that
arrestin 2 acts as a negative regulator of δ-receptor-mediated
convulsions. Second, arrestin 2 knockout mice convulsed
multiple times in response to a single dose of SNC80.
Tolerance to δ-receptor-mediated convulsions is typically
acute and long lasting (Comer et al., 1993; Hong et al., 1998).
In addition, the changes in the electroencephalographic wave-
form produced by SNC80 return to normal baseline activity fol-
lowing the end of catalepsy (Jutkiewicz et al., 2006). To our
knowledge, this is the first report of multiple convulsive events
in response to a δ-receptor agonist in rodents. One possible ex-
planation for this observation is that loss of arrestin 2 produces
these behavioural changes by preventing δ-receptor desensitiza-
tion and/or up-regulating δ-receptor trafficking to the cell mem-
brane resulting in enhanced δ-receptor signalling (Mittal et al.,
2013). However, in the current study, δ-receptor-mediated
antidepressant-like effects and thermal antihyperalgesia were
not significantly altered in arrestin 2 knockout mice. Therefore,
it is possible that the behavioural effects of SNC80 are differen-
tially regulated by arrestin 2 due to differences in regional ex-
pression, behavioural mechanisms and/or signalling down-
regulation and/or tolerance to the convulsive effects of
SNC80. Thus, loss of arrestin 2 could allow signalling pathways
that would normally be terminated to persist and producemul-
tiple convulsive events. Future work will examine whether
arrestin 2 also regulates tolerance to other behavioural effects
of δ-receptor agonists.
Overall, our data demonstrate an important role for Gαo,
but not arrestins, in regulating the acute antihyperalgesic
and antidepressant-like effects of the δ-receptor. However,
δ-receptor-mediated convulsions appear to be negatively
regulated by arrestin 2 and were not altered by manipula-
tions of Gαo function (see Figure 5). Taken together, these
findings suggest that different signalling pathways underlie
the convulsive effects of the δ-receptor, as distinct from the
antihyperalgesic and antidepressant-like effects. Perhaps
due in part to this phenomenon, some δ-receptor agonists
do not produce convulsions at doses far exceeding those
needed to produce antinociception and antidepressant-like
Figure 5
Signalling molecules involved in δ-receptor-mediated behaviours. Alterations to G protein signalling pathway molecules, such as Gαo and RGS
proteins, modified the antihyperalgesic and antidepressant-like effects of the δ-receptor agonist SNC80. However, arrestin 2 appears to act as a
negative regulator of SNC80-induced convulsions.
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effects (Le Bourdonnec et al., 2008; Saitoh et al., 2011;
Chung et al., 2015). However, the properties of δ-receptor
agonists that determine their convulsive nature remain
unclear. Ongoing work will continue to investigate the
signalling mechanisms responsible for the behavioural
effects of different δ-receptor agonists.
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Figure S1 NTG does not alter SNC80-induced convulsions.
Male and female C57BL6wild-typemice were given 10mg·kg1
NTGor vehicle (0.9% saline) i.p. 60min prior to an s.c. injection
of SNC80 or vehicle. Mice were then observed for 30 min for
convulsive behaviours. NTG pretreatment did not signifi-
cantly alter the severity of SNC80 convulsion relative to mice
that received a saline pretreatment.
Figure S2 The time of onset (A) and duration (B) of SNC80-
induced convulsions is not significantly altered in Gαo RGS-
insensitive heterozygous mice (+/GS) compared to wildtype
littermates (+/+).
Figure S3 The time of onset (A) and duration (B) of SNC80-
induced convulsions is not significantly altered in Gαo het-
erozygous knockout mice (+/) compared to wild-type litter-
mates (+/+).
Figure S4 The time of onset (A) and duration (B) of SNC80-
induced convulsions is not significantly altered in arrestin 3
heterozygous (+/) or homozygous (/) knockout mice
compared to wild-type littermates (+/+).
Figure S5 The time of onset (A) and duration (B) of
SNC80-induced convulsions is not significantly altered in
arrestin 2 knockout mice (/) compared to wild-type lit-
termates (+/+). If a mouse exhibited multiple convulsions,
only data related to the first convulsion are shown.
Figure S6 Loss of arrestin 2 does not alter the potency of PTZ
to induce convulsions.
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